Vedolizumab Induces Clinical Response and Remission Across a Range of Baseline Fecal Calprotectin Levels in Patients with Ulcerative Colitis: Results from GEMINI 1
Wyant T, Lewis J, Reinisch W, Dassopoulos T, Ginsburg P, Sands B, Feagan B, Danese S, Roseth A, Rosario M, Yang H, Parikh A, Bressler B. Vedolizumab Induces Clinical Response and Remission Across a Range of Baseline Fecal Calprotectin Levels in Patients with Ulcerative Colitis: Results from GEMINI 1. The American Journal Of Gastroenterology 2014, 109: s486. DOI: 10.14309/00000434-201410002-01638.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply